Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient ≥18 years and \<90 years of age~* Classification of RA according to the ACR/EULAR 2010 criteria~* Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)~* Written informed consent~* Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor~* No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks~* Stable dose of NSAIDs for at least 1 week~Exclusion Criteria:~* • Current treatment with any investigational drug~* Current administration interval of the anti-TNF-alpha agent of \>11 weeks~* Complete destruction of any joint to be investigated by sonography~* Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules~* Initial arthritis manifestations before the age of 17 years~* Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography~* Current severe medical illness requiring hospitalization~* Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent~* Pregnancy or lactation~* Inability of the patient to follow the protocol~* Current treatment with Rituximab (MabThera®)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- single arm ( bDMARD withdrawal ) (Type: EXPERIMENTAL): single arm (bDMARD withdrawal)

Based on this trial design, predict the completion outcome and termination type (if applicable).